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Introduction: Growing recognition of paracrine mechanisms in stem cell plasticity has resulted in considerable
interest in stem cell-derived secretome. The aim of this study was to investigate the effects of lipopolysaccharide
(LPS) preconditioning on the composition and hepatic regenerative activity of adipose-derived stem cell (ASC)
secretome.
Methods: Conditioned medium (CM) and LPS-CM were obtained after culturing human ASCs without or with
low-dose LPS (0.5 ng/mL) for 24 hours. Untreated and thioacetamide-treated mouse AML12 hepatocytes
were incubated for 24 hours with the control medium, LPS (0.5 ng/mL), CM, and LPS-CM and then cell viabilities
were compared. CM and LPS-CM were also intravenously administered to partially hepatectomized mice, and their
effects on liver regeneration were assessed by using liver weight measurements, immunohistochemistry, and
Western blotting.
Results: In the in vitro experiments, LPS preconditioning of ASCs enhanced the mRNA expression levels of
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), hepatocyte growth factor, and vascular endothelial growth
factor, which evoke inflammatory response or liver regeneration. LPS-CM significantly promoted thioacetamide-
damaged AML12 cell viability compared with CM-incubated cells and the control cells (77%, 69%, and 65% P
<0.05). In the in vivo experiment, LPS-CM infusion into the partially hepatectomized mice significantly reduced
serum IL-6 and TNF-α levels compared with the other groups (P <0.05) on days 1 and 2 after partial hepatectomy.
Moreover, LPS-CM infusion enhanced liver regeneration (based on the liver weight changes at day 7 after partial
hepatectomy, 3.73% versus 3.22% in the CM group; P <0.05) and significantly reduced the elevated serum levels of
aspartate transaminase and alanine transaminase (at day 1, P <0.05).
Conclusions: Our results suggest that LPS preconditioning effectively stimulates ASCs to produce the secretome
beneficial to hepatic regeneration. Thus, optimizing ASC secretome profile by LPS preconditioning could be a
promising approach to treat liver diseases by using stem cells.Introduction
Over the last decades, mesenchymal stem cells (MSCs)
have been extensively studied with regard to their poten-
tial implications in regenerative medicine. MSCs have
demonstrated several advantages, including higher avail-
ability, functional plasticity, and lower immunogenicity
[1]. Among the various sources of MSCs, adipose tissue is
gaining more and more interest because large amounts of* Correspondence: sejoonkim@hanmail.net
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by less invasive methods and thus they are considered
major candidates for future regenerative medicine [2].
However, despite the encouraging results of preclinical
studies using ASCs, its clinical application is still hindered
by several limitation factors, including poor growth kinet-
ics, early senescence, and genetic instability during in vitro
expansion, as well as the possibility of malignant trans-
formation [3-5].
Meanwhile, increasing evidence has been accumulating
in support of the notion that the principal mechanism of
stem cell-based therapeutic activity is secretome-relatedis is an Open Access article distributed under the terms of the Creative
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rather than the cells per se can be one way to circumvent
the limitations of cell-based therapy while maintaining its
advantages. The total set of molecules secreted or surface-
shed by stem cells is generally referred to as secretome.
The secretome includes bioactive peptides, including cyto-
kines, chemokines, and growth factors [6,9-11]. These sol-
uble factors are released from ASCs either solitarily or in
the form of extracellular vesicles (EVs). The EVs include
exosome (50 to 100 nm in diameter) and the larger micro-
vesicle (50 to 100 nm in diameter) [12]. EVs are particu-
larly important because they have the ability to transfer
proteins and functional genetic material such as RNA to
other cells [13-15]. Therefore, the use of these cell-free
products may indeed represent an alternative to the ther-
apies based on cell transplantation.
Improving liver regenerative ability after partial hepa-
tectomy (PH) or living donor liver transplantation has
been a primary concern, especially for patients with cir-
rhosis or other functional liver impairment. Recent re-
search indicated that the intravenous administration of
MSCs could enhance liver regenerative ability in the
murine models of either toxin-induced hepatic failure or
PH [16-20]. Moreover, the isolated administration of
secretome, instead of MSCs themselves, has shown the
equivalent liver regenerative ability, demonstrating the
paracrine effect of MSCs [21-23]. The spectrum of regu-
latory factors making the secretome can be shaped by
genetic engineering of ASCs or by modifying their phys-
ical or chemical environment (that is, reconditioning) or
both. It is well established that the composition of ASC
secretome is significantly dependent on culturing condi-
tions; therefore, the optimization of culture methodology
can be the easiest way to obtain a secretome with high
therapeutic potential.
It has been suggested that MSC stimulation with Toll-
like receptor 4 (TLR4) agonists polarizes human MSCs
toward a pro-inflammatory phenotype but that MSC
stimulation with TLR3 agonists polarizes them toward
an immunosuppressive phenotype [24]. Lipopolysacchar-
ide (LPS) is a representative TLR4 agonist and induces
MSCs to release pro-inflammatory cytokines, including
interleukin-1-beta (IL-1β), IL-6, IL-8, IL-12, type I inter-
ferons (IFNs), and tumor necrosis factor-alpha (TNF-α)
[25,26]. Moreover, MSC pretreatment with low, non-
toxic LPS concentrations prior to transplantation has
been shown to increase resistance to tissue damage in
various organs [9,26-28]. Considering these findings, we
suppose that LPS preconditioning of ASCs would har-
ness the ASCs to generate the secretome with higher
liver regenerative ability. In this study, we attained the
ASC secretome under the LPS preconditioning and evalu-
ated its effectiveness in terms of liver regeneration, anti-
inflammation, and organ restorative capacity in bothin vitro and in vivo models. These results could help
determine the optimal culture conditions for obtaining
a high-yield secretome that is most beneficial for liver
recovery.
Methods
Adipose tissue-derived stem cell culture
Human ASCs (third passage) were kindly donated by
Hurim BioCell Company (Seoul, Korea). The institutional
review board of Hurim BioCell Company (registration
number in Korea Center for Disease Control & Preven-
tion: 1-700069-B-N-01) approved the attainment of hu-
man ASCs, and informed consents were obtained from all
of the patients. Cultured ASCs have been shown to display
MSC phenotype: they express the MSC marker CD90 and
do not express hematopoietic markers CD31 and CD34
[29]. ASCs were cultured and ASC secretome was pre-
pared the way we previously described [29].
Preparation of lipopolysaccharide-conditioned medium
ASCs were grown in 100-mm cell dishes (Corning Glass
Works, Corning, NY, USA). After reaching 70% to 80%
confluence, 5.0 × 105 ASCs were cultured in 5 mL of
serum-free low-glucose Dulbecco’s modified Eagle’s
medium (DMEM) (Thermo Scientific, Hemel Hempstead,
UK) with or without LPS in low concentration (0.5 ng/
mL; Sigma-Aldrich, St. Louis, MO, USA) for 24 hours. In
a variety of experiments including intravenous administra-
tion of MSCs, 0.1 mL of 1 × 105 to 1.0 × 106 MSCs has
been used for an injection into a mouse [17,30-32]. In our
protocol, the secretome from 5.0 × 105 ASCs was cultured
in 5 mL of DMEM. Therefore, to obtain the equivalent
amount (0.1 mL) of secretome, the conditioned media
were concentrated 25-fold by using ultrafiltration units
with a 3-kDa-molecular-weight cutoff (Amicon Ultra-PL
3; Millipore, Bedford, MA, USA) after stimulation with or
without LPS. From here on, LPS-CM and CM refer to the
25-fold concentrated conditioned media which had been
obtained from ASCs after stimulation with or without LPS
for 24 hours.
Intravenous administration of conditioned medium and
lipopolysaccharide- conditioned medium in partially
hepatectomized mice
We designed a case–control study to assess the effect of
intravenous administration of CM and LPS-CM by using
8-week-old male BALB/c mice (Damool Science, Daejeon,
Korea). This study was approved by the Institutional
Animal Care and Use Committee of the Clinical Research
Institute at Daejeon St. Mary’s Hospital at the Catholic
University of Korea (institutional review board #CMCDJ-
AP-2014-007). The animals were housed under pathogen-
free conditions and received humane care in accordance
with the criteria outlined in the Guide for the Care and
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National Academy of Sciences (National Institutes of
Health publication 86–23, 1985 revision). Approximately
70% PH was performed under tiletamine-zolazepam sed-
ation (30 mg/kg intraperitoneal Zoletil; Virbac, Nice,
France) [33]. Liver regeneration was expressed as the ratio
(percentage) of liver weight to body weight (LW/BW)
[34-36]. Within 1 hour after PH, the mice were divided
into four experimental groups and were intravenously ad-
ministered 0.1 mL of low-glucose DMEM (control group),
0.5 ng/mL LPS in low-glucose DMEM (LPS group), CM
(CM group), and LPS-CM (LPS-CM group).
Each group included 25 mice (total 100 mice), which
were separated into two subgroups: those used to evaluate
consecutive alterations in serology, such as serum levels of
aspartate transaminase (AST) and alanine transaminase
(ALT) (n = 5), and those that were sacrificed to obtain sera
for enzyme-linked immunosorbent assay (ELISA) and
histologic specimens at specific time points (1, 2, 3, and
7 days) after material administration (n = 20).
Real-time quantitative polymerase chain reaction
Total ASC RNA was extracted by using TRIzol reagent
(Invitrogen, part of Thermo Fisher Scientific, Waltham,
MA, USA) in accordance with the instructions of the
manufacturer. Reverse transcription was performed with
1 μg of RNA, random primers, and M-MLV Reverse tran-
scriptase (Promega, Madison, WI, USA). The primers
used for SYBR green quantitative real-time polymerase
chain reaction (qRT-PCR) were the following: IL-6 for-
ward 5′-CACACAGACAGCCACTCACC-3′ and reverse
5′-TTTTCTGCCAGTGCCTCTTT-3′; TNF-α forward
5′-AACCTCCTCTCTGCCATCAA-3′ and reverse 5′-
GGAAGACCCCTCCCAGATAG-3′; vascular endothelial
growth factor (VEGF) forward 5′-TCTTCAAGCCATC
CTGTGTG-3′ and reverse 5′-ATCTGCATGGTGATGT
TGGA-3′; hepatocyte growth factor (HGF) forward 5′-
TGCTGTCCTGGATGATTTTG-3′ and reverse 5′-AG
TGTAGCCCCAGCCATAAA-3′; and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) forward 5′- GC
ACCGTCAAGGCTGAGAAC-3′ and reverse 5′-TGG
TGAAGACGCCAGTGGA-3′. The reaction was per-
formed by using an Applied Biosystems 7500 Fast
Real-Time PCR System (Life Technologies, Carlsbad,
CA, USA) equipped with a 96-well optical reaction
plate reader. The expression levels of the target genes
were calculated by using the comparative threshold
cycle method and normalized to GAPDH as a house-
keeping gene. The data are presented as the mean ± stand-
ard deviation from three independent experiments.
Enzyme-linked immunosorbent assay
In an in vitro experiment, CM and LPS-CM were col-
lected from each dish and centrifuged at 1,500 revolutionsper minute (rpm) for 5 minutes, and human IL-6 release
was measured by using an ELISA kit (eBioscience Inc.,
San Diego, CA, USA) in accordance with the instructions
of the manufacturer. In an in vivo experiment, concentra-
tions of mouse IL-6 and TNF-α were determined in the
serum of partially hepatectomized mice at 1, 2, and 3 days
after the injection of control medium, LPS, CM, and LPS-
CM by using ELISA kits (eBioscience Inc. and Biolegend
Inc., San Diego, CA, USA).Cell viability assay
A non-tumorigenic mouse hepatocyte cell line AML12
(CRL-2254) was purchased from American Type Culture
Collection (Manassas, VA, USA) and maintained in
DMEM/Ham F12 (Invitrogen) supplemented with 10%
fetal bovine serum (Invitrogen), 1× insulin-transferrin-
selenium-G supplement (Invitrogen), 40 ng/mL dexa-
methasone (Sigma-Aldrich), and 100 ng/mL amphotericin
B (Invitrogen). AML12 cells were plated 1 × 104 cells per
well in 96-well plates and allowed to adhere overnight.
Thereafter, CM or LPS-CM was added, followed by incu-
bation for 24 hours at 37°C. In the TLR4 inhibition test,
prior to incubation with CM or LPS-CM, cells were pre-
treated with TLR4 inhibitor TAK-242 (1 μM; Calbiochem,
La Jolla, CA, USA) or dimethyl sulfoxide (Sigma-Aldrich)
as vehicle control for 1 hour. Then, hepatocyte toxicity
was induced by maintaining AML12 cells in the pres-
ence of 50 mM thioacetamide (TAA) (Sigma-Aldrich).
Normal and TAA-treated AML12 cells were incubated
with the control medium, LPS (0.5 ng/mL), CM, and
LPS-CM, and cell viability was examined by using the
Ez-Cytox cell viability assay kit (Daeil Lab Service Co.,
Ltd, Seoul, Korea).Immunohistochemical analysis of Ki67 expression
Paraffin-embedded tissue sections were deparaffinized in
xylene and rehydrated in a graded series of alcohol. The
antigen was retrieved by heating the sample with 0.01 M
citrate buffer (pH 6.0) in an autoclave (CHS-ACCE-860;
JW Pharmaceutical, Seoul, Korea) at 121°C for 5 minutes.
The sections were placed in 3% hydrogen peroxide for
5 minutes to inactivate the endogenous peroxidase,
blocked for 10 minutes with protein block serum-free
solution (Dako, Glostrup, Denmark), and incubated
overnight at 4°C with the primary rabbit polyclonal anti-
body against Ki67 nuclear antigen (1:300; Abcam, Inc.,
Cambridge, MA, USA) to detect proliferating cells. The
slides were treated with a biotinylated secondary anti-
body for 30 minutes at room temperature, followed by
streptavidin-horseradish peroxidase (HRP) and 3,3′-
diaminobenzidine solution (all from Dako) for another
10 minutes at room temperature, and counter-stained
with hematoxylin.
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The effects of CM and LPS-CM on hepatotoxicity were
assessed in both in vitro (TAA-treated AML12 cells) and
in vivo (partially hepatectomized mice) experiments by
Western blot analysis. TAA-treated AML12 cells incu-
bated with DMEM, LPS, CM, and LPS-CM were lysed
by using the EzRIPA Lysis kit (Atto Corporation, Tokyo,
Japan) and were centrifuged at 12,000 rpm for 15 minutes,
and the supernatants were collected. Liver tissues were
lysed in lysis buffer (Roche Applied Science, Indianapolis,
IN, USA). Protein concentration in the lysates was deter-
mined by using the Bradford reagent (Bio-Rad Laboratories,
Hercules, CA, USA). Equal amounts of protein (30 μg) per
well were separated by SDS-PAGE and electro-transferred
onto nitrocellulose membranes, which were blocked with
5% non-fat milk at room temperature for 1 hour, and incu-
bated with primary antibodies (1:1,000 dilution) against
proliferating cell nuclear antigen (PCNA), phospho-signal
transducer and activator of transcription 3 (p-STAT3)
(Tyr705), STAT3, and β-actin at 4°C overnight and with
HRP-conjugated secondary anti-rabbit and anti-mouse
IgG (1:2,000 dilution) for 1 hour at room temperature
(all from Cell Signaling, Beverly, MA, USA). Specific
immune complexes were detected by using Western
Blotting Plus Chemiluminescence Reagent (Millipore).
Assessment of liver functions
Blood samples were obtained from each mouse and cen-
trifuged for 10 minutes at 10,000 rpm, and the serum
was collected. Concentrations of transaminases AST and
ALT, the indicators of liver injury, were measured by
using the Idexx VetTest Chemistry Analyzer (Idexx La-
boratories Inc., Westbrook, ME, USA).
Statistical analysis
All data were analyzed by using SPSS 11.0 software
(SPSS Inc., Chicago, IL, USA) and are presented as theFigure 1 Effects of lipopolysaccharide (LPS) preconditioning of adipose tiss
pro-inflammatory cytokines. (A) ASCs were cultured in serum-free low-gluc
concentration (0.5 ng/mL) for 24 hours and analyzed for mRNA expression
growth factor (HGF), and vascular endothelial growth factor (VEGF) by quantitat
were collected, concentrated 25-fold, and analyzed for IL-6 concentration by
deviation of four independent experiments (P <0.05). *P <0.05. CM, conditionmean ± standard deviation. Statistical comparisons among
groups were performed by using the Kruskal-Wallis and
Mann–Whitney U tests; the Mann–Whitney U test was
used to compare mean values between two groups, and
the Kruskal-Wallis test was used to compare mean values
among three or more groups. Probability values of P less
than 0.05 were considered statistically significant.
Results
Effects of lipopolysaccharide preconditioning on mRNA
expression and secretion of pro-inflammatory cytokines
IL-6 and TNF-α are representative pro-inflammatory cy-
tokines [37], and HGF and VEGF are well-known hep-
atic mitogens [34,38]. Human ASCs after six or more
passages were incubated with increasing concentrations
of LPS for 24 hours, and mRNA expression of these me-
diators was determined by quantitative PCR. The levels of
these markers were increased at 0.5 ng/mL LPS but there-
after decreased (Figure 1A), indicating that low-dose LPS
preconditioning upregulated mRNA expression of these
mediators. Next, we directly measured human IL-6 con-
centrations in the human ASCs which had been main-
tained with or without 0.5 ng/mL LPS (LPS-CM and CM)
for 24 hours. IL-6 levels were significantly higher in LPS-
CM than in CM (6.19 versus 1.65 ng/mL; P <0.05), dem-
onstrating that low-dose LPS triggers IL-6 secretion by
ASCs (Figure 1B).
Effects of conditioned medium and lipopolysaccharide-
conditioned medium on normal and thioacetamide-
treated AML12 cells
We investigated the effects of CM and LPS-CM on the
proliferation of mouse hepatocyte AML12 cells. Un-
treated and TAA-treated mouse AML12 cells were cul-
tured with control medium, LPS, CM, and LPS-CM and
then cell viabilities were determined. In both untreated
and TAA-treated AML12 cells, LPS-CM groups showedue-derived stem cells (ASCs) on mRNA expression and secretion of
ose Dulbecco’s modified Eagle’s medium with or without LPS in low
of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), hepatocyte
ive polymerase chain reaction. (B) Conditioned media (CM and LPS-CM)
enzyme-linked immunosorbent assay. Values represent mean ± standard
ed medium; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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groups were second (106.5% and 69.6%, respectively) (P
<0.05) (Figure 2A). Moreover, we performed an experi-
ment by using TLR4 inhibitor, TAK-242, to obtain the
clear-cut evidence that the effectiveness of LPS-CM is
driven not by LPS but by LPS-CM. LPS signaling isFigure 2 Effects of conditioned medium (CM) and lipopolysaccharide (LPS
hepatocytes. (A) Untreated and 50 mM thioacetamide (TAA)-treated and TA
with the control medium, LPS (0.5 ng/mL), CM, and LPS-CM and cell viabili
represent mean ± standard deviation of four independent experiments (P <0.
transcription 3 (p-STAT3) and STAT3 in AML12 cells treated as above were anamediated by TLR4 and involves the coordinated produc-
tion of a multitude of inflammatory mediators [24].
Therefore, to block LPS signaling, TAK-242 was supple-
mented to the TAA-treated AML12 cells which had
been cultured with control medium, LPS, CM, and LPS-
CM. TAK-242 treatment did not result in significant)-CM on the viability of normal and hepatotoxic agent-treated mouse
A + TLR4 inhibitor (TAK-242) AML12 cells were incubated for 24 hours
ties were determined by using the Ez-Cytox cell viability assay. Values
05). (B) The expressions of phospho-signal transducer and activator of
lyzed by Western blotting. *P <0.05. TLR4, Toll-like receptor 4.
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gesting no relationship between LPS-CM effectiveness
and LPS/TLR4 signaling.
It is well known that IL-6/STAT3 signaling plays a
crucial role in the mitogenic response in the liver [39].
The expression levels of p-STAT3 were significantly re-
duced in TAA-treated compared with untreated AML12
cells. However, CM reversed the reduction, whereas
LPS-CM caused further increase in the p-STAT3 expres-
sion. Again, TAK-242 treatment did not result in signifi-
cant changes of the p-STAT3 expression in the LPS-CM
group (Figure 2B).
Effect of lipopolysaccharide-conditioned medium on
the secretion of pro-inflammatory cytokines in partially
hepatectomized mice
We investigated whether the injection of CM or LPS-CM
changed serum concentration of IL-6 and TNF-α in
partially hepatectomized mice. Figure 3 shows thatFigure 3 Serum concentrations of tumor necrosis factor-alpha (TNF-α)
and interleukin-6 (IL-6) in partially hepatectomized mice treated with
adipose tissue-derived stem cell-conditioned media (CM). Mice were
intravenously injected with low-glucose Dulbecco’s modified Eagle’s
medium (control), lipopolysaccharide (LPS) (0.5 ng/mL), CM, or LPS-CM
1 hour after partial hepatectomy (PH) and tested for TNF-α (A) and IL-6
(B) serum levels at indicated times after PH (P <0.05). In each group,
five mice were included per time interval (all 60 mice). Values represent
mean ± standard deviation. *P <0.05.serum IL-6 and TNF-α levels peaked at day 2 after PH;
however, administration of LPS-CM effectively lowered
IL-6 and TNF-α levels at that time compared with the
control medium as well as LPS and CM (P <0.05).
Thereafter, these differences disappeared by day 3 after
PH. IL-6 concentration at day 3 after PH, however, was
still significantly lower in the LPS-CM group compared
with the CM group (P <0.05).
Effect of conditioned medium and lipopolysaccharide-
conditioned medium on liver regeneration after PH
We investigated the effects of CM and LPS-CM treat-
ment on liver regeneration in partially hepatectomized
mice by (1) immunohistochemical evaluation of the
number of Ki67-positive cells in the liver on days 1, 2, 3,
and 7 after PH; (2) Western blotting analysis of PCNA
expression on day 2 after PH; and (3) measuring liver
weight on day 7 after PH (Figure 4).
Antigen Ki67 is a nuclear protein associated with the
transcription of ribosomal RNA and therefore is expressed
exclusively in proliferating cells [40]. Figure 4A shows the
representative sections of Ki67-labeled hepatocytes on day
1 after PH. The number of Ki67-positive cells peaked
on day 2 and decreased thereafter in all the groups
(Figure 5B). The LPS-CM mice demonstrated a signifi-
cantly higher number of Ki67-positive cells in the liver
compared with the control, LPS, and CM mice on day
1, 2, and 3 after PH (P <0.05). However, on day 7, the
difference in the number of Ki67-positive cells between
the CM and LPS-CM groups became insignificant.
Hepatocyte expression of PCNA is a well-established
marker of liver regeneration [41]. Western blotting re-
sults indicate that the LPS-CM mice had the highest
PCNA protein levels, followed by the CM group on day
2 after PH (Figure 4C). The same trend was observed
for p-STAT3 expression, which was also the highest in
the LPS-CM-infused mice followed by the CM-infused
mice.
Finally, liver regeneration was assessed on the basis of
LW/BW ratio on day 7 after PH (Figure 4D). Liver regen-
eration rates were calculated as 2.55 ± 0.25, 2.51 ± 0.47,
3.23 ± 0.08, and 3.73 ± 0.33 in the control, LPS, CM, and
LPS-CM groups, demonstrating the highest liver regener-
ation in the LPS-CM group (P <0.05).
Effect of conditioned medium and lipopolysaccharide-
conditioned medium on liver function after PH
We evaluated serum levels of ALT and AST, the bio-
chemical markers indicative of liver damage and hepatic
dysfunction (Figure 5). We first administered LPS, CM,
and LPS-CM to the control mice which did not undergo
PH and identified that the solitary administration of
these materials did not increase liver enzyme levels (data
not shown). Next, partially hepatectomized mice were
Figure 4 Effects of conditioned medium (CM) and lipopolysaccharide (LPS)-CM on liver regeneration in partially hepatectomized mice. Mice were
intravenously injected with low-glucose Dulbecco’s modified Eagle’s medium (control), LPS (0.5 ng/mL), CM, or LPS-CM 1 hour after partial
hepatectomy (PH). (A) Representative micrographs show liver sections stained with anti-Ki67 antibody 24 hours after PH (magnification, 400×).
(B) The percentage of Ki67-positive cells in the liver on days 1, 2, and 3 after PH (P <0.05). (C) Western blotting of liver lysates showing that the
LPS-CM group had the highest expression of PCNA and p-STAT3 on day 2 after PH. (D) Liver regeneration rate (percentage) based on the ratio
(percentage) of liver weight to body weight (LW/BW) on day 7 after PH; the highest regeneration was observed in the LPS-CM group (P <0.05).
*P <0.05. PCNA, proliferating cell nuclear antigen; p-STAT3, phospho-signal transducer and activator of transcription 3; STAT3, signal transducer
and activator of transcription 3.
Figure 5 Effect of conditioned medium (CM) and lipopolysaccharide (LPS)-CM on serum levels of aspartate transaminase (AST) and alanine
transaminase (ALT) in partially hepatectomized mice. Mice were intravenously injected with low-glucose Dulbecco’s modified Eagle’s medium
(control), LPS (0.5 ng/mL), CM, or LPS-CM 1 hour after partial hepatectomy. At day 1 after partial hepatectomy, the LPS-CM-treated mice had
significantly lower AST (A) and ALT (B) levels compared with the other groups (P <0.05). *P <0.05.
Lee et al. Stem Cell Research & Therapy  (2015) 6:75 Page 7 of 11
Lee et al. Stem Cell Research & Therapy  (2015) 6:75 Page 8 of 11administered these materials via the tail vein. Serum
concentrations of liver enzymes AST and ALT peaked at
day 1 after PH and decreased thereafter, reaching near-
normal levels by day 7. At day 1, the LPS-CM group
showed significantly lower AST and ALT levels than the
control and LPS groups (P <0.05), suggesting the accel-
erated restoration of liver function after PH.
Discussion
In this study, it was identified that LPS preconditioning
of ASCs enhanced the expression levels of the media-
tors, particularly involved in the inflammation (IL-6 and
TNF-α) and liver regeneration (HGF and VEGF). Next,
we explored the response of partially hepatectomized
mice to the intravenous administration of LPS-conditioned
medium (LPS-CM) in terms of inflammation, immunosup-
pression, hepatic function, and liver regeneration. Intraven-
ous administration of LPS-CM reduced IL-6 and TNF-α
levels more than control medium, LPS, and CM adminis-
tration did. Furthermore, intravenous administration of
LPS-CM enhanced liver regeneration and significantly re-
duced the elevated serum levels of AST and ALT. The
LPS-CM group also induced higher expressions of p-
STAT3 after PH than the other groups. Considering these
findings, we postulated that activated IL-6/STAT3 path-
way prompted by LPS-CM would be responsible for the
higher liver regenerative ability in the liver. Thus, our re-
sults suggest that LPS preconditioning effectively induces
ASCs to produce a secretome beneficial for hepatocyte
proliferation and liver recovery.
It is widely accepted that most, if not all, cells secrete
large amounts of micro- and nano-vesicles, either consti-
tutively or upon activation signals. In our study, condi-
tioned media, which had been obtained from ASCs,
were concentrated 25-fold by using ultrafiltration units
with a 3-kDa-molecular-weight cutoff. It seems that cells
and larger particles were removed by sequentially in-
creasing the centrifugal forces, and then exosomes were
precipitated by centrifugation of at least 100,000 g for at
least 2 hours. Exosomes, but also other types of microve-
sicles, can operate in a multitude of ways since they con-
tain essentially biological molecules and the solutes that
are present in the parental cells. Exosomes contain a
number of proteins, mRNAs, microRNAs, and lipid mol-
ecules important for intercellular communication. Once
secreted, exosomes can either be taken up by nearby tar-
get cells or travel to more distant sites through the blood
and possibly other biological fluids. Although we did not
identify exosome, we think our secretome contains a
considerable amount of exosome because our way of
obtaining secretome is in line with the way of obtaining
exosome [12,42].
Proteomic research has identified a number of soluble
proteins in the ASC secretome. Basically, mature adiposetissue itself acts as an endocrine organ releasing a wide
range of regulatory proteins, such as leptin, vaspin, resistin,
adiponectin, plasminogen activator inhibitor 1 (PAI-1),
and pro-inflammatory cytokines [43-46], which exert
hormone-like effects through the circulation [46]. ASCs
have also been shown to abundantly secrete these regula-
tory factors, including PAI-1, placental thrombin inhibitor,
pigment epithelium-derived factor, protease C1 inhibi-
tor, and pregnancy zone protein [47-49]. A liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) analysis of the MSC secretome has also detected
187 proteins, which included a number of mediators
related with tissue repair, regeneration, and inflammation
[47]. Therefore, the rationale for using stem cell secretome
is exactly that it provides a unique combination of mul-
tiple regulatory factors that cannot be mechanically repro-
duced and should be used in totality.
In this study, we have shown that ASCs preconditioned
with LPS increased the expressions of pro-inflammatory
mediators, such as IL-6 and TNF-α. A large body of
evidence indicates that MSCs basically possess anti-
inflammatory and immunosuppressive properties [50-57].
Therefore, the reparative function of MSCs observed in so
many injury models may be attributed, at least in part, to
the production of paracrine factors that directly inhibit in-
flammatory and immune responses. However, it was also
observed, though less frequently, that MSCs can induce
inflammatory response [58]. In an attempt to resolve these
conflicting data concerning pro- and anti-inflammatory
properties of MSCs, Bunnell et al. [24] provided a new
MSC paradigm; human MSCs, like monocytes, are polar-
ized into two phenotypes, classified as MSC1 and MSC2
according to the downstream TLR signaling. The para-
digm was based on the observation that TLR4 agonists
(that is, LPS) polarized human bone marrow-derived
MSCs toward a pro-inflammatory property but that TLR3
agonist (that is, poly [I:C]) polarized the MSCs toward an
immunosuppressive property. Our results are in line with
this proposal in that LPS, as a TLR4 agonist, polarized
ASCs to show a pro-inflammatory aspect. However, ASCs
were not completely polarized into the pro-inflammatory
phenotype, judging from the downregulation of systemic
IL-6 and TNF-α levels following LPS-CM administration.
We assumed that these contrasting effects could be ex-
plained by multiple factors, including differences in the
amount and duration of incubation with TLR ligands,
MSC sources, and expression levels of TLR3 and TLR4.
Interestingly, LPS preconditioning of human ASCs in-
duced higher expression of IL-6 and TNF-α in ASCs,
whereas intravenous administration of LPS-CM decreased
serum concentrations of mouse IL-6 and TNF-α. The sur-
gical procedure of PH induces systemic inflammation,
which involves the rise of pro-inflammatory cytokines,
such as IL-6 and TNF-α. IL-6 is secreted by Kupffer cells
Lee et al. Stem Cell Research & Therapy  (2015) 6:75 Page 9 of 11in the liver and by monocytes and macrophages predomin-
antly in the blood [59]. IL-6 is a pleiotropic cytokine which
covers both pro-inflammatory and anti-inflammatory re-
sponses [37]. Pro-inflammatory activities of IL-6 include
recruitment of inflammatory cells and inhibition of regula-
tory T-cell differentiation, all of which are mediated by
binding to the soluble IL-6 receptor (IL-6R) [60,61]. Anti-
inflammatory activities of IL-6 include STAT3-dependent
regulation of hepatocyte proliferation and the induction of
the hepatic acute-phase response [60,61]. These activities
are dependent on the membrane-bound IL-6R. In our ex-
periment, ASCs seems to be not completely polarized into
the pro-inflammatory phenotype. Accordingly, the total
composition of ASC secretome appeared to be directed
toward anti-inflammation, especially in the systemic circu-
lation. However, in the hepatic microenviroment, liver re-
generation appears to be prompted by IL-6, other IL-6
family cytokines, and other mediators, all of which were
derived from LPS-CM.
To the best of our knowledge, we were first to show
that the LPS preconditioning of ASCs induces the re-
lease of mediators with higher liver regenerative ability;
however, the exact mechanism needs to be clarified. The
use of commercially available TLR4-deficient mice
(C3HHEJ) is expected to contribute to the further un-
derstanding of the mechanism. It was well established
that LPS triggers innate immune responses by binding
to TLR4, mainly on antigen-presenting cells via nuclear
factor-kappa-B (NF-κB)-dependent transcriptional events.
In a report, LPS treatment to the bone marrow-derivedFigure 6 Proposed mechanisms by which lipopolysaccharide-conditioned m
mice. It can be postulated that the LPS-preconditioned secretome release
factor-alpha, hepatocyte growth factor, and vascular endothelial growth facto
nuclear factor-kappa-B (NF-κB) activation. These mediators promote hepatocyte
signaling. JAK, Janus kinase; STAT3, signal transducer and activator of transcripMSCs has induced the release of mediators, such as IL-1
β, IFN-λ, and IL-6, and the activation of NF-κB via the
TLR4-MyD88-dependent pathway [62]. This means that
LPS-stimulated activation of NF-κB plays a critical role in
the induction of pro-inflammatory cytokines from bone
marrow-derived MSCs. However, further studies are re-
quired to precisely determine the signal pathway by which
LPS induces ASCs to produce secretome of higher liver
regenerative ability.
IL-6/STAT3 pathways play pivotal roles in regulating
proliferation of hepatocytes, at least in acute liver re-
sponse after hepatectomy in rodents [37,63,64]. There-
fore, it can be postulated that upregulation of IL-6 and
other IL-6 family cytokines has induced higher liver re-
generation by the IL-6/gp130-mediated STAT3 signaling
pathway. In our study, the secretome obtained from
LPS-preconditioned ASCs showed the highest liver re-
generative ability and expressions of p-STAT3 in both
the in vitro and in vivo models. Therefore, we could
think that LPS-CM promotes liver regeneration by way
of IL-6/STAT3 pathway. Upon binding to membrane-
bound IL-6Rs on hepatocytes, IL-6 family cytokines
induce gp130 dimerization and the subsequent phos-
phorylation of gp130-associated Janus kinases (JAKs),
which leads to STAT3 activation, followed by liver
regeneration [59].
Considering these findings, we propose a possible
mechanism to explain how LPS preconditioning of ASCs
enhances liver regenerative ability (Figure 6). In our pro-
posed mechanism, LPS coupled with TLR4 on ASCsedium (LPS-CM) induces liver regeneration in partially hepatectomized
s a variety of mediators-including interleukin-6 (IL-6), tumor necrosis
r—from adipose tissue-derived stem cells (ASCs) by way of intracellular
proliferation by way of various signaling pathways, including IL-6/STAT3
tion 3; TLR4, Toll-like receptor 4.
Lee et al. Stem Cell Research & Therapy  (2015) 6:75 Page 10 of 11induces ASCs to release pro-inflammatory cytokines,
such as IL-6 and TNF-α. LPS also increases the release
of the mediators with higher liver regenerative ability,
such as HGF and VEGF from ASCs. The total set of
molecules secreted or surface-shed by LPS-preconditioned
ASCs promotes liver regeneration, especially by way of ac-
tivating IL-6/STAT3 signaling pathway.Conclusions
We have shown that LPS preconditioning of ASCs in-
duced the secretion of pro-inflammatory mediators with
high hepatoregenerative activity, thereby maximizing the
therapeutic potential of the ASC secretome. This was
evidenced by the fact that LPS-CM improved the prolif-
erative and regenerative properties of hepatocytes in
both in vitro and in vivo experiments. Our results suggest
that LPS preconditioning effectively stimulates ASCs to
produce a secretome with the composition beneficial for
liver regeneration and repair. Thus, optimizing the ASC
secretome by LPS preconditioning could be a promising
approach to prevent liver damage or support hepatic func-
tion or both.Abbreviations
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